Danaher Quarterly Revenues Advanced 12%, Net Income Up 1%
- Scott Peters
- U.S.A. New York City
-
Danaher Corp said first quarter 2022 revenues rose 12% driven by a 4% increase in Covid-19 related testing revenues. Net income was flat. Diagnostic segment revenues in the quarter rose 21.5% followed by 9.5% growth in the Life Sciences segment.
Danaher Corp said first quarter 2022 net revenues increased 12% to $7.7 billion, net income increased 1% to $1.7 billion, and diluted earnings per share $2.31 compared to $2.29 a year ago.
COVID-19 related testing drove sales higher by 4%.
Operating margins declined 80 basis points to 28.3% from 29.1% in the quarter a year ago.
Life Sciences segment revenues rose 9.5% to $3.9 billion and operating profit margin declined 370 basis points to 28.8%.
Diagnostics segment revenues increased 21.5% to $2.6 billion and operating margin improved 480 basis points to 33.5%.
Environmental & Applied Solutions segment revenues rose 2.5% to $1.16 billion and operating margin fell 480 basis points to 20.3%.
The Washington, D.C. based conglomerate manufactures industrial, medical and commercial products including leading brands Beckman Coulter, Leica, and Sciex.
Guidance and Outlook
The company guided non-GAAP base business core revenues growth which excluding acquisitions and currency translations in the second quarter in the mid-single digit percent range, which includes an approximately 200 to 300 basis point headwind from the COVID-19 related shutdowns in China.
For the full year 2022, the company continues to expect non-GAAP base business core revenue growth will be in the high-single digit percent range.
Rainer M. Blair, President and Chief Executive Officer, stated, "We had a good start to the year with results exceeding our initial expectations. Our team successfully navigated a dynamic environment to deliver double digit core revenue growth, approximately 10% adjusted earnings per share growth and $2.0 billion of operating cash flow, despite difficult prior year comparisons.
This performance was broad based with all three of our segments delivering high-single digit or better core revenue growth. We believe our strong execution combined with investments in innovation have driven market share gains in many of our businesses."
Annual Returns
Company | Ticker | 2025 | 2024 | 2023 |
---|---|---|---|---|
Danaher Corporation | DHR | 0% | -1% | -15% |